Catalent (CTLT) Receives ‘Analyst’ Rating

Catalent (CTLT) : Zacks Investment Research ranks Catalent (CTLT) as 4, which is a Sell recommendation. 3 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. A total of 5 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 8 research analysts is 2.25, which indicates as a Buy.

Catalent (CTLT) : 5 Wall Street analysts covering Catalent (CTLT) believe that the average level the stock could reach for the short term is $26.4. The maximum price target given is $30 and the minimum target for short term is around $23, hence the standard deviation is calculated at $2.7.


Also, Major Brokerage house, Wells Fargo upgrades its ratings on Catalent (NYSE:CTLT). According to the latest information available, the shares are now rated Outperform by the analysts at the agency. Previously, the analysts had a Market Perform rating on the shares. The rating by the firm was issued on June 21, 2016.

Catalent (NYSE:CTLT): After opening at $24.19, the stock dipped to an intraday low of $24.06 on Thursday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $25.28 and the buying power remained strong till the end. The stock closed at $25.27 for the day, a gain of 4.64% for the day session. The total traded volume was 2,651,306. The stocks close on the previous trading day was $24.15.

Catalent, Inc. is a provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. The Companys segments include Oral Technologies, Medication Delivery Solutions, and Development and Clinical Services. The Oral Technologies segment provides advanced oral delivery technologies, including formulation, development and manufacturing of oral dose forms for prescription and consumer health products across all phases of a molecules lifecycle. The Medication Delivery Solutions segment provides formulation, development and manufacturing services for delivery of drugs and biologics, administered through injection, inhalation and ophthalmic routes, using both traditional and advanced technologies. The Development and Clinical Services segment provides manufacturing, packaging, storage and inventory management for drugs and biologics in clinical trials.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.